AstraZeneca

The 'Type 2 Diabetes - Pipeline Insight, 2024' report by ResearchAndMarkets.com provides insights into 75+ companies and 80+ pipeline drugs for Type 2 Diabetes, covering clinical and nonclinical stage products, therapeutic assessments, and inactive pipeline products. Key drugs include Eli Lilly's LY-3209590, Tonghua Dongbao's THDB0206, Rivus Pharmaceuticals' HU6, AstraZeneca's AZD5004, Sciwind Biosciences' XW014, and Suzhou Alphamab's KN056. The report highlights collaborations, mergers, acquisitions, and licensing activities, and assesses emerging trends and technologies in Type 2 Diabetes therapeutics.

The European Medicines Agency recommended osimertinib (Tagrisso) for unresectable NSCLC with EGFR mutations, based on the LAURA trial showing an 84% reduction in disease progression risk. Median PFS was 39.1 months with osimertinib vs 5.6 months with placebo, with ongoing OS follow-up.

NMPA approved Zorifertinib Hydrochloride Tablets (Zorifer®), a Class 1 innovative drug developed by Alpha Biopharma, for first-line treatment of adult patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with EGFR exon 19 deletion or exon 21 (L858R) substitution mutation and central nervous system (CNS) metastases. Zorifertinib is the first drug to launch a registration clinical trial specifically for advanced NSCLC with CNS metastases, demonstrating superior ability to control intracranial lesions and significant benefits in overall progression-free survival (PFS).

Yorvipath, the first hormone treatment for hypoparathyroidism, received FDA approval in August. The drug, developed by Ascendis Pharma, replaces missing PTH to restore calcium levels. Patient testimonials highlight significant improvements in quality of life. Additionally, MBX Biosciences and Septerna Therapeutics have made strides with their respective treatments, MBX 2109 and SEP-786, aiming to address the condition's challenges. AstraZeneca's acquisition of Amolyt Pharma for $800 million underscores the growing interest in hypoparathyroidism treatments.

Biotechnology Market to grow at 13.9% CAGR from 2024-2031, driven by health, agriculture, and industrial applications. Valued at USD 1.21 Trillion in 2022, it is expected to reach USD 3.90 Trillion by 2031.

AstraZeneca’s Andexxa faces potential withdrawal after a US FDA advisory committee raised safety and efficacy concerns.

Hefei, China, exemplifies rapid innovation growth, doubling its economic output to $140 billion, driven by the MIC2025 policy aiming for high-tech self-sufficiency. Despite progress in renewables and biopharmaceuticals, challenges like US trade restrictions and a focus on government priorities may hinder creativity and semiconductor advancements.

The UAE is investing in genomics to revolutionize healthcare, with initiatives like the Emirati Genome Programme and the National Genome Strategy. These efforts aim to personalize medicine, improve diagnostics, and enhance public health. Challenges include ethical implications, data protection, and regulatory compliance.

Fanaroff: Research grants from American Heart Association and National Institutes of Health; consulting fees from Abbott Laboratories. Vora: Consulting fees from Medtronic. Mehran: Institutional research grants from AstraZeneca, Bayer, Beth Israel Deaconess, Bristol Myers Squibb/Sanofi, CSL Behring, Eli Lilly/Daiichi Sankyo, Medtronic, Novartis, OrbusNeich; consulting fees from Boston Scientific, Abbott Vascular, Medscape, Siemens Medical Solutions, Roivant Sciences Inc, Sanofi; consulting (no fees) for Regeneron Pharmaceuticals Inc; institutional consulting fees from Abbott Vascular, Spectranetics/Phillips/Volcano Corporation, Bristol Myers Squibb, Novartis, Watermark Research; Executive committee member for Janssen Pharmaceuticals and Bristol Myers Squibb; <1% equity in Claret Medical and Elixir Medical. Granger: Research grants from Bayer, Boehringer Ingelheim, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Armetheon, AstraZeneca, US Food and Drug Administration, GlaxoSmithKline, The Medicines Company, Medtronic Foundation, Medtronic Inc, Novartis; consulting fees from Bayer, Boehringer Ingelheim, Boston Scientific, Bristol Myers Squibb, Daiichi Sankyo, Janssen, Pfizer, Abbvie, Armetheon, AstraZeneca, Eli Lilly, Gilead, GlaxoSmithKline, Hoffmann-La Roche, The Medicines Company, National Institutes of Health, Novartis, Sirtex, Verseon, Apple, Medscape, LLC, Merck, Novo Nordisk, Roche Diagnostics, Rho Pharmaceuticals. Goodman: Research grant support and/or speaker/consulting honoraria from Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol Myers Squibb, CSL Behring, Daiichi-Sankyo, Eli Lilly, Esperion, Fenix Group International, Ferring Pharmaceuticals, GlaxoSmithKline, HLS Therapeutics, Janssen/Johnson & Johnson, Luitpold Pharmaceuticals, Matrizyme, Merck, Novartis, Novo Nordisk A/C, Pfizer, Regeneron, Sanofi, Servier, Tenax Therapeutics, Heart and Stroke Foundation of Ontario/University of Toronto, Canadian Heart Research Centre and MD Primer, Canadian VIGOUR Centre, Duke Clinical Research Institute, PERFUSE. Aronson: Employee of Bristol Myers Squibb. Windecker: Institutional research and educational grants from Abbott, Amgen, Bayer, BMS, CSL Behring, Boston Scientific, Biotronik, Edwards Lifesciences, Medtronic, Polares, Sinomed. Alexander: Research grants from Bristol Myers Squibb, Boehringer Ingelheim, AstraZeneca, CryoLife, CSL Behring, US Food and Drug Administration, National Institutes of Health, Sanofi, VoluMetrix; consulting fees from Pfizer, Bristol Myers Squibb, AbbVie Pharmaceuticals, CSL Behring, Novo Nordisk, Portola Pharmaceuticals, Quantum Genomics, Teikoku Pharmaceuticals, VA Cooperative Studies, Zafgen. Lopes: Research grants from Bristol Myers Squibb, Pfizer, Amgen, Inc, GlaxoSmithKline, Medtronic PLC, Sanofi Aventis; consulting fees from Bristol Myers Squibb, Pfizer, Boehringer Ingelheim, Bayer AG. The other authors report no conflicts.

The Global Acute Migraine Drugs Market is projected to grow at a CAGR of 8.58% from 2023 to 2030, reaching USD 8.75 Billion by 2030, driven by increasing migraine prevalence, pharmaceutical advancements, and demand for fast-acting treatments.